Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for Zp1846
Complete the form below to unlock access to ALL audio articles.
Helsinn Healthcare has announced that it has signed a partnering agreement with Zealand Pharma, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to treat chemotherapy-induced diarrhea (CID), a debilitating condition affecting patients undergoing cancer treatment with a range of chemotherapies.
Under the terms of the agreement, Helsinn Healthcare will receive a worldwide exclusive license to ZP1846 and will be responsible for all further development, regulatory approvals, manufacturing, marketing and sales of the compound either on its own or through its sublicensees.
In return Helsinn Healthcare will pay Zealand Pharma development milestones and sales milestones. In addition, Zealand Pharma will receive royalties on future sales and Zealand Pharma retains the marketing rights to the Nordic countries. The total value of the non royalty portion of the partnership is valued at € 140 million.
Zealand Pharma has applied its knowledge of peptide optimization and its proprietary SIP® technology to develop ZP1846, one of a series of novel peptides that specifically enhance the growth and function of the lining of the intestine. ZP1846 has completed Phase I in humans in the US.
Zealand Pharma’s pre-clinical studies have demonstrated that ZP1846 is useful in the prevention and/or treatment of injuries to the intestinal epithelium caused by chemotherapy treatment, resulting in a reduction in the incidence of chemotherapy-induced diarrhea.
